Aldeyra - ALDX Enterprise Value-to-Revenue Multiple

Public company logo of Aldeyra Therapeutics (ALDX)

The EV-to-revenue ratio for Aldeyra Therapeutics (ALDX) correlates with the scaling of production via external contractors in Massachusetts, with the value fixed at 0.00. This trend is further supported by the development of allergy and dry eye remedies to target the mass market, as well as the utilization of backup warehouses to ensure stable clinical trials without supply chain disruptions.

Aldeyra Therapeutics, Inc. (ALDX): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Aldeyra Therapeutics, Inc. (ALDX)

- share price and consensus valuation forecast:
Fundamental valuation:Aldeyra Therapeutics Inc. (ALDX)
Mass-produced product of aldeyra.com

Aldeyra Therapeutics (ALDX) operates in a clinical research phase without active sales of ophthalmological drugs. The EV/Sales ratio compares the total enterprise value to revenue, eliminating the impact of debt load on the valuation. This metric allows for the determination of the degree of undervaluation of an asset stripped of its liabilities. For companies without a commercial base, this serves as an indicator of speculative potential. By analyzing the EV/Sales valuation chart, an investor can identify the risk of capital becoming trapped while awaiting FDA approval.